Merck: Marches Forward, One of The Best Big Pharma Picks Of 2023 (NYSE:MRK)
Merck's Q1 2023 earnings exceeded expectations, bolstered by blockbuster drugs Keytruda and Gardasil, with a raised FY23 outlook. See why MRK stock is a Buy.
Solskin
Post earnings update to thesis
We maintain a buy rating on Merck (NYSE: MRK) after Q1 2023 earnings that exceeded our expectations, showcasing robust ...
Read More
Other Stories in Business
- NRAI opposes private-label food delivery by Swiggy, Zomato; to take legal action against food delivery giants
- Devon Energy Stock: A Top Energy Rebound Play For 2025 (NYSE:DVN)
- XFoil 2 - World's First Gyro Stabilized Hydrofoil
- Axis Securities initiates coverage on JSW Energy with a buy call; target price Rs 800
- RIL shares in focus as Bernstein, Jefferies turn bullish after recent fall, see up to 36% upside
- Amazon Set To Benefit From Mexico's Import Tariffs Affecting Temu, Shein — Analysts See Window Of Opportunity For Established Players - MercadoLibre (NASDAQ:MELI), Amazon.com (NASDAQ:AMZN)
- Nvidia Is Looking Good For The 2025 Calendar Year (NVDA)
- Bill Gates' net worth: How Microsoft's co-founder spends his $160 billion, including properties, cars, and philanthropy
- - ????? ???? ????? ????? ???? ??? ????? ???? ??????
